Cargando…

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab

Metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG-1), is an oncoprotein closely related to the development of breast cancer. However, few studies have been done on the expression and clinical significance of MTDH in human epidermal growth factor receptor-2 (HER-2) positive breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xinle, Cai, Lijing, Ye, Feng, Li, Mengqi, Ma, Li, Geng, Cuizhi, Song, Zhenchuan, Liu, Yueping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739014/ https://www.ncbi.nlm.nih.gov/pubmed/31490377 http://dx.doi.org/10.1097/MD.0000000000016937

Ejemplares similares

Mucoepidermoid carcinoma of the breast: Four case reports and review of the literature
por: Cheng, Meng, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant female: A case report
por: Tang, Tiantian, et al.
Publicado: (2020)

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
por: Ji, Dongmei, et al.
Publicado: (2020)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
por: Ren, Xiaofei, et al.
Publicado: (2023)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review
por: Wei, Hua, et al.
Publicado: (2021)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Molecular Modification of Metadherin/MTDH Impacts the Sensitivity of Breast Cancer to Doxorubicin
por: Song, Zhenchuan, et al.
Publicado: (2015)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

HER2-positive pure mucinous breast carcinoma: A case report and literature review
por: Zhao, Xingjuan, et al.
Publicado: (2020)

Better survival in PMRT of female breast cancer patients with >5 negative lymph nodes: A population-based study
por: Wang, Haiyong, et al.
Publicado: (2017)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study
por: Aksoy, Suleyman Ozkan, et al.
Publicado: (2020)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
por: Chen, Jim-Ray, et al.
Publicado: (2017)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
por: Tasdoven, Ilhan, et al.
Publicado: (2022)

Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report
por: Cao, Yong, et al.
Publicado: (2019)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Successful use of minimal invasive debridement plus negative pressure wound therapy under skin flap and axillary region for refractory postmastectomy seroma: A STROBE-compliant retrospective study
por: Esen, Ebru, et al.
Publicado: (2022)

Using a novel T-lymph node ratio model to evaluate the prognosis of nonmetastatic breast cancer patients who received preoperative radiotherapy followed by mastectomy: An observational study
por: Wang, Yang, et al.
Publicado: (2017)

Prognosis of COVID-19 in patients with breast cancer: A protocol for systematic review and meta-analysis
por: Sheng, Zhijuan, et al.
Publicado: (2020)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
por: Wang, Haoqi, et al.
Publicado: (2022)

Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report
por: Wu, Hai-Bo, et al.
Publicado: (2017)

The effects of case management for breast cancer patients: A protocol for systematic review and meta-analysis
por: Chai, Yong, et al.
Publicado: (2022)

High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer
por: Li, Yanqing, et al.
Publicado: (2019)

Advanced breast cancer with cachexia: A case report
por: Liu, Nan, et al.
Publicado: (2021)

Impact of lifestyle and psychological stress on the development of early onset breast cancer
por: Li, Ping, et al.
Publicado: (2016)

Metaplastic breast carcinoma composed of epithelial–myoepithelial carcinoma and squamous cell carcinoma: A case report
por: Zhu, Jian, et al.
Publicado: (2018)

Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics
por: Li, Juncheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tr9045ji0gv29jra4sh3kshupj